These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 28966234)

  • 1. Emerging and Diverse Functions of the EphA2 Noncanonical Pathway in Cancer Progression.
    Zhou Y; Sakurai H
    Biol Pharm Bull; 2017; 40(10):1616-1624. PubMed ID: 28966234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crucial roles of RSK in cell motility by catalysing serine phosphorylation of EphA2.
    Zhou Y; Yamada N; Tanaka T; Hori T; Yokoyama S; Hayakawa Y; Yano S; Fukuoka J; Koizumi K; Saiki I; Sakurai H
    Nat Commun; 2015 Jul; 6():7679. PubMed ID: 26158630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein kinase A can block EphA2 receptor-mediated cell repulsion by increasing EphA2 S897 phosphorylation.
    Barquilla A; Lamberto I; Noberini R; Heynen-Genel S; Brill LM; Pasquale EB
    Mol Biol Cell; 2016 Sep; 27(17):2757-70. PubMed ID: 27385333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular stress induces non-canonical activation of the receptor tyrosine kinase EphA2 through the p38-MK2-RSK signaling pathway.
    Zhou Y; Oki R; Tanaka A; Song L; Takashima A; Hamada N; Yokoyama S; Yano S; Sakurai H
    J Biol Chem; 2023 May; 299(5):104699. PubMed ID: 37059179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting EphA2: a promising strategy to overcome chemoresistance and drug resistance in cancer.
    Veiga RN; de Azevedo ALK; de Oliveira JC; Gradia DF
    J Mol Med (Berl); 2024 Apr; 102(4):479-493. PubMed ID: 38393661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crosstalk of the EphA2 receptor with a serine/threonine phosphatase suppresses the Akt-mTORC1 pathway in cancer cells.
    Yang NY; Fernandez C; Richter M; Xiao Z; Valencia F; Tice DA; Pasquale EB
    Cell Signal; 2011 Jan; 23(1):201-12. PubMed ID: 20837138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Non-canonical Activation of Receptor Tyrosine Kinases in Cancer Progression].
    Sakurai H
    Yakugaku Zasshi; 2017; 137(2):141-144. PubMed ID: 28154322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting.
    Wykosky J; Debinski W
    Mol Cancer Res; 2008 Dec; 6(12):1795-806. PubMed ID: 19074825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis.
    Fang WB; Brantley-Sieders DM; Parker MA; Reith AD; Chen J
    Oncogene; 2005 Nov; 24(53):7859-68. PubMed ID: 16103880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine kinase activity of EphA2 promotes its S897 phosphorylation and glioblastoma cell proliferation.
    Hamaoka Y; Negishi M; Katoh H
    Biochem Biophys Res Commun; 2018 May; 499(4):920-926. PubMed ID: 29626472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphoproteomic profiling of NSCLC cells reveals that ephrin B3 regulates pro-survival signaling through Akt1-mediated phosphorylation of the EphA2 receptor.
    Ståhl S; Branca RM; Efazat G; Ruzzene M; Zhivotovsky B; Lewensohn R; Viktorsson K; Lehtiö J
    J Proteome Res; 2011 May; 10(5):2566-78. PubMed ID: 21413766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoietin-Producing Hepatoma Receptor Tyrosine Kinase A2 Modulation Associates with Protective Effect of Prone Position in Ventilator-induced Lung Injury.
    Park BH; Shin MH; Douglas IS; Chung KS; Song JH; Kim SY; Kim EY; Jung JY; Kang YA; Chang J; Kim YS; Park MS
    Am J Respir Cell Mol Biol; 2018 Apr; 58(4):519-529. PubMed ID: 29216437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein kinase C phosphorylates the EphA2 receptor on serine 892 in the regulatory linker connecting the kinase and SAM domains.
    Gehring MP; Pasquale EB
    Cell Signal; 2020 Sep; 73():109668. PubMed ID: 32413552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer.
    Kinch MS; Carles-Kinch K
    Clin Exp Metastasis; 2003; 20(1):59-68. PubMed ID: 12650608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EphA2-dependent molecular targeting therapy for malignant tumors.
    Biao-xue R; Xi-guang C; Shuan-ying Y; Wei L; Zong-juan M
    Curr Cancer Drug Targets; 2011 Nov; 11(9):1082-97. PubMed ID: 21933105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EphA2 Receptor Unliganded Dimers Suppress EphA2 Pro-tumorigenic Signaling.
    Singh DR; Ahmed F; King C; Gupta N; Salotto M; Pasquale EB; Hristova K
    J Biol Chem; 2015 Nov; 290(45):27271-27279. PubMed ID: 26363067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of EPHA2 receptor destabilizes adherens junctions via a RhoA-dependent mechanism.
    Fang WB; Ireton RC; Zhuang G; Takahashi T; Reynolds A; Chen J
    J Cell Sci; 2008 Feb; 121(Pt 3):358-68. PubMed ID: 18198190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progranulin/EphA2 axis: A novel oncogenic mechanism in bladder cancer.
    Buraschi S; Neill T; Xu SQ; Palladino C; Belfiore A; Iozzo RV; Morrione A
    Matrix Biol; 2020 Nov; 93():10-24. PubMed ID: 32417448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EphA2 is a key effector of the MEK/ERK/RSK pathway regulating glioblastoma cell proliferation.
    Hamaoka Y; Negishi M; Katoh H
    Cell Signal; 2016 Aug; 28(8):937-45. PubMed ID: 27132626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteolysis of EphA2 Converts It from a Tumor Suppressor to an Oncoprotein.
    Koshikawa N; Hoshino D; Taniguchi H; Minegishi T; Tomari T; Nam SO; Aoki M; Sueta T; Nakagawa T; Miyamoto S; Nabeshima K; Weaver AM; Seiki M
    Cancer Res; 2015 Aug; 75(16):3327-39. PubMed ID: 26130649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.